🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Sanofi India Limited SANOFI NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.sanofi.com/en/india/investors

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.

READ MORE ›
₹3,097.10
-48.63% 1Y

Market & Price

Market Cap
₹7,132.81 Cr
Current Price
₹3,097.10
High / Low (52W)
₹6,186.84 / ₹3,097.10
Beta
0.23

Valuation

Stock P/E
23.04
Industry PE
37.60
Forward P/E
17.30
PEG Ratio
-
Book Value
₹325.31
Price to Book
9.52
P/S
4.02
EV/EBITDA
15.04
Dividend Yield
7.75%

Profitability & Returns

ROCE
58.48%
ROE
-
ROA
-
Profit Margin
17.46%
Op Margin
28.33%
EPS (Latest Qtr)
₹44.55
EPS (TTM)
₹134.41

Balance Sheet & Liquidity

Debt/Equity
2.38
Quick Ratio
-
Current Ratio
-
Debt
₹17.80 Cr
Total Assets
₹1,254.80 Cr
Current Assets
₹800.60 Cr
Working Capital
₹309.20 Cr

Ownership

Promoter Holding
60.60%
Chg in Prom Hold
-
FII / Inst Holding
24.12%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹6,887.71 Cr
Total Revenue (TTM)
₹1,773.80 Cr
EBITDA
₹457.85 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹2.30 Cr
Gross Margin
49.04%
Payout Ratio
142.74%

Growth (CAGR)

Revenue 5Y
-12.56%
Profit 5Y
-19.26%
Revenue (YoY)
-11.90%
Earnings (YoY)
-14.10%

PROS

  • Healthy ROCE of 58.5%.
  • Attractive dividend yield of 7.75%.

CONS

  • Revenue declined at -12.6% CAGR over 5 years.
  • Earnings shrank at -19.3% CAGR over 5 years.
  • Trading 49.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SANOFI Sanofi India Limited NSEPHARMA 3,097.10 23.04 ₹7,132.81 Cr 7.75% 58.48% - -12.56% -19.26%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue -514.90 Cr535.90 Cr406.30 Cr419.80 Cr472.30 Cr
Cost of Revenue -249.80 Cr240.50 Cr208.70 Cr208.10 Cr234.30 Cr
Gross Profit -265.10 Cr295.40 Cr197.60 Cr211.70 Cr238.00 Cr
Operating Expenses -156.40 Cr133.10 Cr111.80 Cr130.90 Cr104.20 Cr
Operating Income -108.70 Cr162.30 Cr85.80 Cr80.80 Cr133.80 Cr
EBITDA -132.20 Cr175.20 Cr103.60 Cr93.10 Cr147.20 Cr
Interest Expense -40.00 L30.00 L40.00 L60.00 L30.00 L
Pretax Income -122.20 Cr165.30 Cr94.10 Cr83.00 Cr137.90 Cr
Tax Provision -30.90 Cr45.80 Cr24.60 Cr21.30 Cr35.30 Cr
Net Income -91.30 Cr119.50 Cr69.50 Cr61.70 Cr102.60 Cr
Diluted EPS -39.6451.8930.1826.7944.55

Profit & Loss (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -2,727.20 Cr1,981.60 Cr1,989.00 Cr1,823.40 Cr
Cost of Revenue -1,243.70 Cr967.10 Cr998.10 Cr905.90 Cr
Gross Profit -1,483.50 Cr1,014.50 Cr990.90 Cr917.50 Cr
Operating Expenses -817.90 Cr561.20 Cr537.20 Cr463.50 Cr
Operating Income -665.60 Cr453.30 Cr453.70 Cr454.00 Cr
EBITDA -907.90 Cr569.80 Cr471.10 Cr483.70 Cr
Interest Expense -1.70 Cr1.70 Cr1.50 Cr1.70 Cr
Pretax Income -864.30 Cr528.50 Cr431.40 Cr444.70 Cr
Tax Provision -243.70 Cr163.90 Cr117.70 Cr118.00 Cr
Net Income -620.60 Cr602.90 Cr413.50 Cr326.70 Cr
Diluted EPS -269.47261.78179.54141.85

Compounded Sales Growth

5 Years:-12.56%
1 Year:-11.90%

Compounded Profit Growth

5 Years:-19.26%
1 Year:-14.10%

Stock Price Performance

1 Year:-48.63%
6 Months:-28.69%
3 Months:-23.07%
1 Month:-9.10%

Balance Sheet (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -2,071.70 Cr1,714.80 Cr1,611.80 Cr1,254.80 Cr
Current Assets -1,610.30 Cr1,248.00 Cr1,126.80 Cr800.60 Cr
Cash & Equivalents -1,004.90 Cr394.50 Cr283.80 Cr262.90 Cr
Inventory -408.00 Cr663.80 Cr499.80 Cr311.60 Cr
Receivables -129.10 Cr131.70 Cr230.00 Cr176.70 Cr
Total Liabilities -795.90 Cr699.60 Cr751.20 Cr505.60 Cr
Current Liabilities -740.60 Cr651.30 Cr736.50 Cr491.40 Cr
Long Term Debt -----
Total Debt -23.60 Cr19.00 Cr19.30 Cr17.80 Cr
Total Equity -1,275.80 Cr1,015.20 Cr860.60 Cr749.20 Cr
Shares Outstanding -2.30 Cr2.30 Cr2.30 Cr2.30 Cr

Cash Flows (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -398.70 Cr230.40 Cr461.70 Cr438.30 Cr
Investing Cash Flow -650.90 Cr37.50 Cr-19.20 Cr-11.30 Cr
Financing Cash Flow --1,582.70 Cr-878.30 Cr-392.40 Cr-447.90 Cr
Capital Expenditure --22.20 Cr-34.30 Cr-36.40 Cr-25.70 Cr
Free Cash Flow -376.50 Cr196.10 Cr425.30 Cr412.60 Cr
Net Change in Cash --533.10 Cr-610.40 Cr50.10 Cr-20.90 Cr

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -54.4%51.2%49.8%50.3%
Operating Margin % -24.4%22.9%22.8%24.9%
Net Margin % -22.8%30.4%20.8%17.9%
ROE % -48.6%59.4%48.0%43.6%
ROCE % -50.0%42.6%51.8%59.5%

Shareholding Pattern

Insiders
60.60%
Institutions
24.12%
Public Float
61.21%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SANOFI

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space